Placeholder Image

字幕列表 影片播放

  • Unknown: There are roughly 6 million people living with

  • Alzheimer's in the U.S.; a figure that is expected to more 3

  • than double by 2050. The memory-robbing disease kills

  • more than 120,000 Americans a year, making it the sixth

  • leading cause of death.

  • Alzheimer's disease is a devastating disease of

  • progressive dementia, where people can lose various aspects

  • of their cognitive functioning, their ability to remember key

  • things and people.

  • Genius not aware of the fact that she can ask me the same

  • question 10 times 10 minutes, oh maybe nine and a half.

  • The US has spent billions on research but still hasn't been

  • able to develop a drug that targets the cause of the

  • disease.

  • We know that it's a costly disease and the burden of that

  • cost continues to grow exponentially. A drug

  • for any company that could treat Alzheimer's successfully would

  • be seen as just a goldmine for Wall Street and the huge gift to

  • society. Now one

  • biotech company thinks it's cracked Alzheimer's tricky code

  • and a drug known as aducanemab now sold as Aduhelm. This

  • is an approval for Biogen This is a huge stock event to

  • 50% pop on this FDA approval. But Biden's reported only a

  • fraction of estimated sales, the company's share price has nearly

  • halved. Major insurers haven't decided whether to cover the

  • treatment, which Biogen originally priced at roughly

  • $56,000 per year. But now the company is bringing that down by

  • about 50% to hopefully boost sales. In all this comes as the

  • FDA itself phases investigations into its edge home decision,

  • which went against the advice of its own advisors.

  • There's been a real mixed reception among doctors because

  • of the lack of completely convincing data supporting

  • whether the drug works.

  • So the question is who will be prescribing this? Who will be

  • monitoring it? Who will have access to it and who's going to

  • pay for it?

  • The US spends roughly $3 billion on Alzheimer's and dementia

  • research every year. That's up 360%. Over the past five years,

  • spending on people with Alzheimer's is said to cost

  • Medicare $599 billion by 2050.

  • The fact is, is that Alzheimer's is not just a disease of the

  • individual who has it. It is a burden on also individuals who

  • are caregivers as well. In 2020, there are over 11 million

  • Americans who are providing unpaid care for individuals with

  • Alzheimer's, that unpaid care is costly to them and to their

  • family.

  • I'm Eugenia Zukerman, and I have Alzheimers

  • I'm Dick Novik retired from the broadcasting business to be able

  • to take care of my wife. Once I heard she was diagnosed with

  • Alzheimer's. Eugenia was diagnosed three years ago, every

  • senior walked around the house with the glasses on their

  • foreheads and wear my glasses. But this got beyond that this

  • got to you know, it constantly asked me the same question a

  • certain amount of disorientation.

  • My daughters were saying to me Mom, something is wrong with

  • you. You're not sounding okay. We have to take you to the

  • hospital and get you tested. I said no way. But of course, I

  • ended up being taken to the hospital and being looked at

  • very carefully.

  • One of the biggest shocks to us was if you go to any other

  • specialist, gastroenterologist and they give you a medicine for

  • your stomachache. with Alzheimer's, there has been

  • really no commonly prescribed medication.

  • Alzheimer's is a notoriously difficult disease to treat.

  • But there are a couple drugs available there, you know, at

  • this point many decades old, and they can help with some of the

  • symptoms associated with Alzheimer's disease, but in

  • general, they don't work very well.

  • So there hadn't been a new Alzheimer's drug that proved in

  • almost two decades when ad you helm came along, and nothing out

  • there to try to actually affect the underlying drivers of the

  • disease.

  • That's where Biogen comes in. In recent years, his portfolio of

  • other drugs has faced growing generic competition. In 2020,

  • the company posted $13.4 billion in revenue, and near six and a

  • half percent drop year over year, researchers designed Agia

  • home to target one of the diseases defining

  • characteristics.

  • What happens with an Alzheimer's disease is that there's a faulty

  • cleavage of amyloid in a sense that it results in the

  • production of these insoluble and sticky amyloid beta we call

  • them and when this forms, what happens is that that accumulate

  • in the brain and around it, surrounding it are signs of

  • inflammation, oxidation and brain cell death.

  • So Lily has a very similar drug to Biogen is called Diana Mab,

  • which it has been developing and had some really promising

  • earlier stage results that showed not just that it clears

  • the amyloid plaques from the brain but also that there is an

  • effect on cognition.

  • But the path to an FDA approved Alzheimer's drug has been

  • riddled with failures. Over 200 potential medicines failed their

  • trials over the past decade, and in early 2019 Aduhelm almost

  • became one of them.

Unknown: There are roughly 6 million people living with

字幕與單字

影片操作 你可以在這邊進行「影片」的調整,以及「字幕」的顯示

B1 中級 美國腔

阿茲海默(What’s The Controversy Behind Biogen’s Alzheimer’s Drug?)

  • 11 3
    joey joey 發佈於 2022 年 01 月 06 日
影片單字